EFPIA - NEWSLETTER

EFPIA Newsletter 03 March 2022

News

05 October 2022 Pharmaceutical industry response to the war in Ukraine

Supporting people affected by the war

02 March 2022 EFPIA statement on the Commission response to the European Parliament non-legislative resolution...

We are committed to the science-based phase-in of methods to replace the use of animals for scientific purposes and...

Blogs

28 February 2022 What do rare cancers and rare diseases have in common?

Rare Diseases Day: Now is the time to put rare cancers in all policies, addressing gaps in diagnosis, treatment and...

Rare Disease Day | My Mission Possible is to help make treatments for rare disease less rare

Dirk Vander Mijnsbrugge

Vice President Medical Affairs Pfizer Rare Disease on Gene Therapy

Selena Freisens

M.D. Head Medical Affairs, Global Rare Diseases at Chiesi

Mirella Ezban

Scientific Vice President, Novo Nordisk

Max Wegner

Senior Vice President, Head of Regulatory Affairs, Bayer

Events

17 MAR 2022

The shake-up of orphan and pediatric rules Virtual event

Organised in partnership with POLITICO

Learn more →

29 MAR 2022

DIA Europe 2022 Hybrid conference (virtual - Brussels)

Advancing Health Priorities

Learn more →

What we are reading

Data sharing holds key to progress on rare diseases in Europe 28 February 2022 (Financial Times)

The EU’s Industrial Strategy: Blessing or Curse for Knowledge-intensive Industries? 01 March 2022 (ECIPE)

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
Communications@efpia.eu

▶